Samjin Pharmaceutical Selected for MOTIE's World-Class Plus Project
Advancing Innovative New Drugs and Developing Formulation and ADC Platform Technologies
Securing Four Years of R&D Support
"Full-Scale Global Technology Licensing of New Drugs"
Samjin Pharmaceutical announced on April 7 that it has been selected for the "World-Class Plus Project Support Program" by the Ministry of Trade, Industry and Energy. This program supports midsize companies with research and development (R&D), exports, financial services, and consulting. It aims to identify and foster companies with high growth potential in advanced industries such as biotechnology.
Samjin Pharmaceutical was selected for its project titled "Advancement of Innovative New Drugs and Development of Antibody-Drug Conjugate (ADC) Platform Technology." The company's key pipeline, the immunology and inflammation treatment "SJN314," and its ADC platform were major areas of evaluation.
Through this project, Samjin Pharmaceutical plans to expand the indications for SJN314, establish its ADC platform, and advance its controlled-release formulation technology. SJN314 has completed preclinical studies and is preparing to enter clinical trials.
The company intends to leverage its ADC platform and formulation technologies to expand technology licensing and global commercialization in the future. Currently, Samjin Pharmaceutical has 16 new drug candidates in its pipeline and invests about 12% of its revenue in research and development.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Samjin Pharmaceutical representative stated, "We plan to expand global technology licensing based on our core pipeline and platform technologies."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.